Advancement To Revolutionize Oral Drug Delivery
Zengen, Inc. announced today that its revolutionary drug delivery technology will be used in the new Chloraseptic® Relief Strips(tm), the only medicated oral strip for the treatment of sore throat. Zengens proprietary technology is the first to use drug active ingredients in an oral strip.
"We are excited to be part of the new generation of Chloraseptic products," said R. Steven Davidson, chief executive officer of Zengen. "Our technology holds promise to revolutionize the drug delivery industry because it marks the first time that drug active ingredients have been delivered utilizing an oral strip. This method is effective and convenient for consumers and may be more cost efficient for manufacturers."
The medicated oral strip is structured as a proprietary bilayer system. This system eliminates the use of irritating solvents and reduces damage due to heat and moisture, maintaining the integrity and efficacy of the active ingredients.
Certain auxiliary compounds used with the bilayer system can assist with rate of dissolution, water solubility, mucous adhesion and coating on the exterior film layer. For instance, depending on the auxiliary compounds used, Zengens oral strips can be manufactured to dissolve quickly or over an extended period of time, regulating the release of active material.
Previous technologies have proven too harsh, exposing the medical compound to extreme heat, moisture, compromising solvents and other irritants. With the creation of Chloraseptic Relief Strips, Zengen has established a new process which prevents the exposure to these harmful irritants and incorporates additional compounds to make the strips more suitable for various drug delivery needs.
"Chloraseptic Relief Strips bring true innovation to the cough/cold category and are a fitting extension of the Chloraseptic product line," said Elise Donahue, president and chief operating officer of Prestige Brands International. "Zengens technology has allowed us to make our product more convenient, accessible and modern for our consumers."
About Chloraseptic Relief Strips
New Chloraseptic Relief Strips are the first and only product of its kind to provide immediate and convenient relief of sore throat pain in an oral strip. The oral strips contain the active ingredients benzocaine and menthol. Chloraseptic Relief Strips will be available in major retail markets and drug stores beginning in September, 2003. The strips will be sold in two 20-count packs at a suggested retail price of $5.29.
About Zengen, Inc.
Zengen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative products to treat and prevent infection and inflammation through application of its proprietary peptide technologies. Zengens novel molecules offer broad-based anti-infective and anti-inflammatory solutions for multiple diseases and disorders, ranging from yeast infection to transplantation, and have the potential to significantly alter the way these diseases are treated. Through its wholly-owned subsidiary, InnoZen, Inc., Zengen develops and markets, or outlicenses, over-the-counter health products. In June 2003, InnoZen launched new OptiZen lubricating eye drops for instant relief from symptoms associated with Computer Vision Syndrome including eye dryness, burning and irritation. For more information about Zengen, please visit www.zengen.com
About Prestige Brands International
Prestige Brands is a consumer products company that was formed in 1999 for the purpose of buying and marketing popular consumer products. Prestiges first acquisition was Prell Shampoo, which the company purchased in November 1999. Subsequently, Prestige Brands purchased Chloraseptic Throat Sprays and Lozenges in March 2000, Comet Cleanser in 2001, and the Clear Eyes and Murine brands of eye drops and ear care products in 2003. Prestiges expertise is in marketing well-known brands to consumers via targeted advertising and promotion as well as identifying and developing new innovative line extensions that better meet consumers needs.
Kumiko Hakushi | Ruder Finn, Inc.
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy